COVID-19 Response: Local Logistics     National Effort

Serum biomarkers identification by iTRAQ and verification by MRM: S100A8/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma [Mass Spectrometry - Metabolomics Facility].

You are here

COVID-19 Response: Local Logistics     National Effort

TitleSerum biomarkers identification by iTRAQ and verification by MRM: S100A8/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma [Mass Spectrometry - Metabolomics Facility].
Publication TypeJournal Article
Year of Publication2019
AuthorsArora A, Patil V, Kundu P, Kondaiah P, Hegde AS, Arivazhagan A, Santosh V, Pal D, Somasundaram K
JournalSci Rep
Volume9
Issue1
Pagination2749
Date Published2019 Feb 26
ISSN2045-2322
Abstract

Despite advances in biology and treatment modalities, the prognosis of glioblastoma (GBM) remains poor. Serum reflects disease macroenvironment and thus provides a less invasive means to diagnose and monitor a diseased condition. By employing 4-plex iTRAQ methodology, we identified 40 proteins with differential abundance in GBM sera. The high abundance of serum S100A8/S100A9 was verified by multiple reaction monitoring (MRM). ELISA and MRM-based quantitation showed a significant positive correlation. Further, an integrated investigation using stromal, tumor purity and cell type scores demonstrated an enrichment of myeloid cell lineage in the GBM tumor microenvironment. Transcript levels of S100A8/S100A9 were found to be independent poor prognostic indicators in GBM. Medium levels of pre-operative and three-month post-operative follow-up serum S100A8 levels predicted poor prognosis in GBM patients who lived beyond median survival. In vitro experiments showed that recombinant S100A8/S100A9 proteins promoted integrin signalling dependent glioma cell migration and invasion up to a threshold level of concentrations. Thus, we have discovered GBM serum marker by iTRAQ and verified by MRM. We also demonstrate interplay between tumor micro and macroenvironment and identified S100A8 as a potential marker with diagnostic and prognostic value in GBM.

DOI10.1038/s41598-019-39067-8
Alternate JournalSci Rep
PubMed ID30808902